SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing CNS-directed gene therapies for unmet needs in the neurodegenerative diseases, announced today that it has received from the United States Patent and Trademark Office (USPTO) U.S. Patent No. 12,460,262, entitled “METHODS […]

(NasdaqGM:BGL),(NasdaqGM:BGLWW), Total committed capital of US $140m for restart of Bogoso and Prestea mine secured from two separate institutional backers (US $75m Equity Line of Credit, still undrawn, and new US $65m1 secured loan) Blue Gold ready to drop litigation with the Government of Ghana if the lease dispute is resolved instantly Restart of Bogoso

(PinkSheets:BSEM),(Pinksheets:BSEM), Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived

(TSX-V:ABM),(OTC US:ABNAF),(Other OTC:ABNAF),(Boerse Frankfurt – Freiverkehr:R26),(Boerse Frankfurt – Freiverkehr:ML1), Vancouver, BC, Nov. 05, 2025 (GLOBE NEWSWIRE) — Aben Gold Corp. (TSX-V: ABM) (OTCID: ABNAF) (Frankfurt: ML1) (“Aben” or “the Company”) announces that it has received a Class 1 Quartz Approval from the Liard First Nations, Ross River Dena Council, and the Government of the Yukon

(NYSE MKT:SACH), – Company to Host Webcast and Conference Call – BRANFORD, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) (the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results

(NASDAQ:BOLD), Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN

(NasdaqGM:FHTX), Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+ breast cancer; IND-ready in 2026 Robust preclinical anti-tumor activity and favorable

(NASDAQ:BCRX), RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 12:00 p.m. ET. The link to the live audio webcast and replay of the presentation may be

(NASDAQ:BMEA), The Company's investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A Phase I study of BMF-650 in healthy obese patients is currently enrolling with data expected first half of 2026 In a rodent model of type 2 diabetes (“T2D”), icovamenib in

(NasdaqGM:LRMR), In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of nomlabofusp to alter FA's disease course relative to a worsening